ITP Support Association/LinkedIn
Aug 10, 2026, 13:36
Ianalumab and the Changing Landscape of ITP Treatment – ITP Support Association
ITP Support Association shared a post on LinkedIn:
“We asked Tung Le at Imperial College Hammersmith Hospital what Novartis have been working on. The answer: Ianalumab, studied across four trials between 2023 and 2025, each looking at a different stage of ITP:
- First-line – newly diagnosed patients, started within 28 days of diagnosis
- Second-line – patients who hadn’t responded to first-line therapy
- Refractory – patients who’d already been through multiple lines of treatment
Recruitment for these particular trials has now closed, but patients who took part are still being followed up, some for two to three years so far, helping researchers understand the longer-term picture.
Research like this is how new treatment options eventually make their way to patients. Curious what’s currently recruiting?
We keep an up-to-date list on our website.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Aug 10, 2026, 14:30Erik Rafflenbeul: Preventing the Need for Coronary Stenting
-
Aug 10, 2026, 14:26Tabassum Rahman: Aboriginal Women’s Voices in Cardiovascular Health Research
-
Aug 10, 2026, 14:01Your Diagnosis Does Not Define Your Future – Glanzmann’s Research Foundation
-
Aug 10, 2026, 13:06Azin Kheirkhah: New Research on OSE-IgM Antibodies and Age-Related Macular Degeneration
-
Aug 10, 2026, 11:20Jean-Jacques Kiladjian: Interferon-Alpha in Polycythemia Vera Balancing Efficacy and Autoimmune Risk
-
Aug 10, 2026, 11:19Rishdha Roshad: Hemodilution vs Transfusion on CPB – Balancing Oxygen Delivery and Microcirculatory Flow
-
Aug 10, 2026, 11:15Julie McMullen: CSANZ Heart Failure Stream – Latest Updates on Atrial Myopathy and AFib
-
Aug 10, 2026, 11:07Praveen Kaudlay: A Deep Dive into Hemophilia Care Progress with Dr. Suresh Hanagavadi
-
Aug 10, 2026, 10:59Christian Heiss: Paclitaxel Efficacy in Dialysis-Dependent PAD